Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Alkem Laboratories Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Shareholder Meeting / Postal Ballot-Outcome of AGM
This is with reference to the 44th Annual General Meeting of the Company held today i.e. on Friday, 31st August, 2018 at 10.30 a.m. at Nehru Centre Auditorium, Dr Annie Besant Road, Worli, Mumbai 400 018. Please find encelosed herewith the details regarding the brief proceedings of the 44th Annual General Meeting (AGM) of the Company and the details regarding the voting results of the business transacted at the said AGM in the prescribed format.... Announcement under Regulation 30 (LODR)-Press Release / Media Release
Update on US FDA Inspection at manufacturing facility at California, USA This is to inform you that US FDA had conducted an inspection at the manufacturing facility of Company's wholly owned subsidiary S&B; Pharma Inc., located at California, USA from 8th August, 2018 to 10th August, 2018. At the end of the inspection, no Form 483 was issued. Kindly take note of the same. Closure of Trading Window
We refer to our earlier communication dated 28th June, 2018 regarding closure of trading window (for the purpose of financial results for the quarter ended 30th June, 2018) starting from 29th June, 2018 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended 30th June, 2018 are communicated to the Stock Exchanges.... Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June, 2018.
In continuation of our letter dated 31st July, 2018 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2018, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 10th... Outcome of Board Meeting
In continuation of our letter dated 31st July, 2018 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2018, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 10th... Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that US FDA had conducted an inspection at the Company's manufacturing facility located at Baddi, Himachal Pradesh from 6th August, 2018 to 10th August, 2018. At the end of the inspection, no Form 483 was issued. Kindly take note of the same. Notice Of The 44Th Annual General Meeting (AGM) And Annual Report For FY 2017-2018
Please find enclosed herewith the Notice of the 44th Annual General Meeting of the Company scheduled to be held on Friday, 31st August, 2018 at 10.30 a.m. at Nehru Centre Auditorium, Dr. Annie Besant Road, Worli, Mumbai - 400 018 alongwith the Annual Report for the financial year 2017-2018. The same is also available on the website of the Company at www.alkemlabs.com Kindly take the same on record. Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q1FY19 financial results will be held on Friday, 10th August, 2018 at 5.00 P.M. Please find attached herewith the conference call details. Kindly take note of the same. Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited ('Company')
ALKEM LABORATORIES LTDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2018 ,inter alias, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2018.